High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy - Sorbonne Université
Journal Articles Clinical Hematology International Year : 2021

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Ameet Patel
Shi Huang
Yan Ru Su
  • Function : Author
Kimberly B Dahlman
  • Function : Author
Kelsey Tomasek
Yueli Zhang
  • Function : Author
Richard T O’neil
  • Function : Author
Jamye F O’neal
  • Function : Author
Isik Turker
  • Function : Author
Douglas B Johnson
  • Function : Author
Joe-Elie Salem
Javid J Moslehi
  • Function : Author
Olalekan Oluwole
  • Function : Author
  • PersonId : 1139489

Abstract

Retrospective studies suggest that chimeric antigen receptor T-cell (CAR T) therapy may lead to cardiac injury, but this has not been assessed systematically or prospectively. In this prospective study of 40 patients who received CAR T, we systematically measured high-sensitivity troponin T (hsTropT) and N-terminal pro-B natriuretic peptide (NTproBNP) at baseline and on day 1, days 7, and 21 after CAR T. Biomarker elevations with respect to timepoint and cytokine release syndrome (CRS) status were examined using repeated measure analysis of variance. hsTropT did not differ with time or with the presence of grade 2 CRS. Median hsTropT was 12.1 ng/L [interquartile range (IQR): 9.2, 20.1] at baseline, 13.1 ng/L (IQR: 9.6, 24.2) at day 1, 11.9 ng/L (IQR: 9.6, 18.0) at day 7, and 15.3 ng/L (10.8, 20.2) at day 21. In contrast, NTproBNP rose on day 1 (PWilcox = 0.0002) and day 7 (PWilcox = 2.7 × 10−5), and the degree of elevation differed by the presence of grade 2 CRS (Pinteraction = 0.002). Median NTproBNP was 179 pg/mL (IQR: 116, 325) at baseline, 357 pg/mL (IQR: 98, 813) at day 1, 420 pg/mL (IQR: 239, 1242) at day 7, and 177 pg/mL (IQR: 80, 278) at day 21. In conclusion, hsTropT l did not differ across timepoints after CAR T therapy, but NTproBNP rose at day 7, the prognostic implications of which should be the target of future research, as the indications for this therapy expand.

Domains

Hematology
Fichier principal
Vignette du fichier
125959231.pdf (802.23 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03456455 , version 1 (30-11-2021)

Identifiers

Cite

Jiun-Ruey Hu, Ameet Patel, Shi Huang, Yan Ru Su, Kimberly B Dahlman, et al.. High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. Clinical Hematology International, 2021, 3 (3), pp.96. ⟨10.2991/chi.k.210718.001⟩. ⟨hal-03456455⟩
13 View
28 Download

Altmetric

Share

More